Results 211 to 220 of about 17,568,133 (310)

Low-dose atropine for myopia progression in children: a 2017-2024 systematic review and meta-analysis of randomized placebo-controlled trials. [PDF]

Front Med (Lausanne)
Magurno L, Lang M, Zapata M, Gallo JE.
europepmc   +1 more source

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers

British Journal of Clinical Pharmacology, EarlyView.
Aim Fluorescence‐guided surgery enhances intraoperative visualization of anatomical structures. Nizaracianine is a near‐infrared fluorescent agent that is exclusively renally cleared in animal models. It enables real‐time ureteral imaging and identification, potentially reduces risk of injury and facilitates assessment before surgical closure.
Lisanne K. A. Neijenhuis, Cedric M. W. Pesch, John V. Frangioni, Alexander L. Vahrmeijer, Jacobus Burggraaf, Naomi B. Klarenbeek   +5 more
wiley   +1 more source

Antiseizure monotherapy with imepitoin or phenobarbital in feline idiopathic epilepsy: a multicenter, single-blinded, randomized and placebo-controlled study. [PDF]

Front Vet Sci
Charalambous M, Tipold A, Volk HA, Knebel A, Hünerfauth EI, Von Klopmann T, Rupp S, Broeckx BJG, Bhatti SFM.   +8 more
europepmc   +1 more source

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

Efficacy and safety of Shatavari root extract in women with Polycystic Ovarian Syndrome: a randomized, double-blind, placebo-controlled trial. [PDF]

Front Endocrinol (Lausanne)
Mhatre Y, Jadhav P, Malik A, Srivathsan M, Langade D.   +4 more
europepmc   +1 more source

The Ethics of Placebo-Controlled Trials

Journal of Bone and Mineral Research, 2003
openaire   +5 more sources

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Pulsed Electromagnetic Field Therapy for Mild-to-Moderate Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. [PDF]

J Cachexia Sarcopenia Muscle
Lau KKL, Chen ASC, Fu CHY, Ng JP, Ong MTY, Yung PSH, Lui PPY.   +6 more
europepmc   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source